KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Research & Development (2016 - 2025)

CRISPR Therapeutics AG's Research & Development history spans 11 years, with the latest figure at $83.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 16.43% year-over-year to $83.5 million; the TTM value through Dec 2025 reached $284.8 million, down 8.2%, while the annual FY2025 figure was $284.8 million, 8.2% down from the prior year.
  • Research & Development for Q4 2025 was $83.5 million at CRISPR Therapeutics AG, up from $58.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $123.2 million in Q2 2022 and bottomed at $36.4 million in Q4 2021.
  • The 5-year median for Research & Development is $83.4 million (2021), against an average of $85.9 million.
  • The largest annual shift saw Research & Development skyrocketed 184.46% in 2022 before it dropped 28.31% in 2025.
  • A 5-year view of Research & Development shows it stood at $36.4 million in 2021, then surged by 184.46% to $103.6 million in 2022, then fell by 8.12% to $95.1 million in 2023, then dropped by 24.6% to $71.7 million in 2024, then grew by 16.43% to $83.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Research & Development are $83.5 million (Q4 2025), $58.9 million (Q3 2025), and $69.9 million (Q2 2025).